Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide +/- Epoetin Beta in MDS
NCT01718379Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Jul 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Started Jul 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01718379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718379.